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Transcription factor 7 like 2 (TCF7L2) rs7903146 polymorphism has been associated with 
metabolic disturbance and cardiovascular disease. The aim of this study was to analyze the 
association between TCF7L2 rs7903146 polymorphism and potential disturbances on the 
lipid profile in human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected 
patients. We performed a cross-sectional study on 263 HIV/HVC-coinfected patients. 
TCF7L2 polymorphism was genotyped by GoldenGate assay. The analysis was performed 
by linear and logistic regression under a dominant model of inheritance. The variables 
analyzed were total cholesterol (TC), high-density lipoprotein (HDL-C), low-density lipoprotein 
(LDL-C), non HDL-C, and triglycerides. Patients harboring rs7903146 TT/TC genotype 
showed a diminished concentration of TC (p=0.003), LDL-C (p=0.004), HDL-C (p=0.012), 
non HDL-C (p=0.013); lower percentage of TC≥200 mg/dL (p=0.038) and higher percentage 
of HDL≤40 mg/dL (p=0.023). In addition, we observed that rs7903146 was differently related 
to fasting serum lipid levels according to HCV-genotype (HCV-GT). With regard to HCV-GT1 
patients, rs7903146 TT/TC genotype was associated with lower levels of HDL-C (adjusted 
arithmetic mean ratio (aAMR)=0.91; p=0.049) and elevated percentage of patients with HDL-
C≤40 mg/dL (adjusted odds ratio (aOR)=3.26; p=0.003). For HCV-GT3 patients, rs7903146 
TT/TC genotype was associated with lower serum values of TC (aAMR=0.81; p=0.037), LDL-
C (aAMR=0.67; p=0.001), non HDL-C (aAMR=0.75; p=0.002) and reduced percentage of 
TC≥200 mg/dL (aOR=0.089; p=0.037). In conclusion, the TCF7L2 rs7903146 TT/TC 
genotype was associated with lower levels of TC, LDL, and HDL in HCV-GT3 patients, and 
lower levels of HDL-C in HCV-GT1 patients; suggesting a role in the cardiovascular disease 
and a potential use as biomarker in HIV/HCV-coinfected patients. 
 





Chronic hepatitis C (CHC) has become a major cause of morbimortality in human 
immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients in high-income 
countries (1). An increased risk of dyslipidemia, atherosclerosis and cardiovascular diseases 
has been associated with the HCV and HIV infections, and also with the specific antiretroviral 
therapies (2-6). In this way, the HCV infection has been related to steatosis and metabolic 
abnormalities such as insulin resistance, type 2 diabetes mellitus (T2DM), and dyslipidemia 
(reductions in total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-
density lipoprotein cholesterol (LDL-C) (7, 8). The coinfection with HIV modify the natural 
history of chronic hepatitis C (CHC), generating higher rates of liver steatosis, cirrhosis and 
end stage liver diseases than HCV monoinfected patients (9, 10). Although the published 
data suggest that combination antiretroviral therapy (cART) might be beneficial for HIV/HCV-
coinfected patients (10), it has been linked to lipodystrophy, insulin resistance, type 2 
diabetes mellitus, and lipid disturbances, including higher levels of TC, LDL-C, and 
triglyceride (TG); and decreased levels of HDL-C (11-14).  
Dyslipidemia is a main risk factor of cardiovascular disease in patients with HIV infection, 
which is related to cART (15, 16). Thus, the risk of myocardial infarction is proportional to the 
time of cART (17) and it is also demonstrated that it could be partly explain by the 
dyslipidemia caused by these drugs (18). In this way, the increased cardiovascular risk is 
associated particularly with prolonged use of protease inhibitors, which are usually 
associated with a less favorable lipid profile, in particular elevated TG and TC (15). 
Moreover, nonnucleoside reverse transcriptase inhibitors show, in general, the best lipid 
profile of all antiretrovirals because they are associated with an increase in HDL-C and a 
significant reduction in TC/HDL-C ratio (15). Finally, the effects of nucleoside reverse 
transcriptase inhibitors on lipids are generally mild and there is a high degree of 
heterogeneity (11). 
The mechanisms leading to lipid disturbances are not completely understood, but there is a 
growing evidence that genetic background may contribute to individual differences in this 
pathology (19-21). The transcription factor 7 like 2 (TCF7L2) is located on chromosome 
10q25.3. This gene is integrated by 18 exons which suffers alternative splicing regulation. 
TCF7L2 is part of the Wnt/β-catenin signaling pathway, which is involved in glucose 
homeostasis and lipid metabolism (22). Recently, the rs7903146 (C>T) single nucleotide 
polymorphism (SNP) located at TCF7L2 intron 5 region, has been strongly associated with 
metabolic syndrome (23), type 2 diabetes mellitus (24), dyslipidemia (25) and cardiovascular 
disease (26, 27) in general population. However, to the best of our knowledge, the effect of 
TCF7L2 polymorphism has not been studied in HIV/HCV-coinfected patients. 
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The aim of this study was to analyze the association between TCF7L2 rs7903146 
polymorphism and potential disturbances on the lipid profile in HIV/HCV-coinfected patients. 
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METHODS 
Study design and patients 
We carried out a cross-sectional study on 263 non-diabetic HIV/HCV-coinfected patients from 
Hospital Gregorio Marañón (Madrid, Spain) between September 2000 and July 2009. All 
subjects included in our study were HCV treatment-naive patients who were potential 
candidates for HCV therapy.  
The inclusion criteria for the study were HIV/HCV-coinfected patients who were over 18 years 
and HCV treatment-naïve, detectable HCV-RNA by polymerase chain reaction, negative 
hepatitis B surface antigen, availability of a DNA sample, no clinical evidence of hepatic 
decompensation, no diabetes mellitus, and stable cART for at least 6 months before study 
entry or no need for cART according to treatment guidelines used in the study period (28, 
29). Patients with active opportunistic infections, pregnant women, active drug and/or alcohol 
addiction and other concomitant diseases or conditions were excluded. Thus, 495 HIV/HCV 
coinfected patients met the criteria described above, 293 of them had a DNA sample 
available for genotyping, but only 263 patients were included in our study (12 patients were 
excluded due to DNA genotyping errors and 18 due to absence of relevant clinical data. All 
patients were of European descent. 
The study was conducted in accordance with the Declaration of Helsinki and patients gave their 
written consent for the study. The Institutional Review Board and the Research Ethic Committee 
of the Instituto de Salud Carlos III (ISCIII) approved the study. 
Epidemiological and clinical data 
The main clinical and epidemiological data of 263 patients analyzed were obtained from 
medical records. Body mass index (BMI) was calculated as the weight in kilograms divided by 
the square of the height in meters. The duration of HCV infection for patients with a history of 
intravenous drug use (IDU) was estimated starting from the first year they shared needles and 
other injection paraphernalia, which are the most relevant risk practices for HCV transmission 
(30). 
Biochemical data 
Biochemistry panel was measured by using an autoanalyzer Hitachi 912 (Boehringer 
Mannheim, Germany) in fasting patients. We collected data of TC, HDL-C, and TG. LDL-C was 
calculated by Friedewald estimation (LDL-C= TC - HDL-C - (TG/5)) (31). Non HDL-C was 
calculated as TC minus HDL-C (32). The degree of insulin resistance was estimated for each 
patient by using the homeostatic model assessment (HOMA), according the following formula 
(33): fasting plasma glucose (mmol/l) x fasting serum insulin (mU/l) / 22.5.  
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Liver biopsy 
Liver biopsies were performed on 211 out of 263 patients basis following the recommendations 
of the Patient Care Committee of the American Gastroenterological Association (34) as we 
previously described (35). Liver fibrosis and necroinflammatory activity were estimated 
according to Metavir score as follows: F0, non-fibrosis; F1, mild fibrosis; F2, significant fibrosis; 
F3, advanced fibrosis; and F4, definite cirrhosis. Activity grade was scored as follows: A0, non-
activity; A1, mild activity; A2, moderate activity; A3, severe activity (36). 
Genotyping of TCF7L2 polymorphism 
Genomic DNA was extracted from peripheral blood with Qiagen columns (QIAamp DNA 
Blood Midi/Maxi; Qiagen, Hilden, Germany). DNA samples were genotyped at the Spanish 
National Genotyping Center (CeGen; http://www.cegen.org/) for the rs7903146 (C>T) SNP at 
TCF7L2 gene using GoldenGate® assay with VeraCode® Technology (Illumina Inc. San 
Diego, CA, USA).  
Statistical analysis 
All statistical tests were performed with the Statistical Package for the Social Sciences 
(SPSS) 19.0 software (IBM Corp., Chicago, USA). All p-values were two-tailed and statistical 
significance was defined as p<0.05.  
For the description of the study population, p-values were estimated with nonparametric 
tests: Mann-Whitney U test was used for continuous variables and Chi-square test for 
categorical variables.  
Hardy-Weinberg equilibrium (HWE) for TCF7L2 rs7903146 polymorphism was assessed by 
a Chi-square test, considering equilibrium when p>0.05.  The genetic association study was 
carried out under a dominant genetic model for T allele (CT/TT vs. CC), which was the model 
that best fit our data. On the one hand, lineal regression analyses were used to investigate 
the association between rs7903146 and continuous outcome variables, which were log10-
transformed. This test provides the differences between groups and the arithmetic mean ratio 
(AMR), which provides us the increase of the value with presence of T allele. On the other 
hand, logistic regression analyses were used to investigate the association of rs7903146 with 
categorical outcome variables. This test gives the association between groups through the 
odds ratio (OR), which indicates the likelihood of having the outcome in the CT/TT genotypes 
versus CC genotype. Each regression analysis was always adjusted by the most significant 
co-variables associated with each one of the outcome variables, avoiding the over-fitting of 
the regression. The co-variables were selected by “Stepwise” algorithm (at each step, factors 
are considered for removal or entry: a p-value for entry and exit of 0.15 and 0.20, 
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respectively), including gender, age, body mass index (BMI), nadir CD4+ T-cells, 
undetectable HIV viral load (<50 copies/mL), time with cART, specific antiretroviral drugs 
used by each patient (zidovudine, stavudine, didanosine, tenofovir, abacavir, efavirenz, 
ritonavir, lopinavir, saquinavir and fosamprenavir), HCV viral load ≥500,000 IU/ml and 
significant fibrosis (F≥2). Besides, we also included two polymorphisms (ADIPOQ rs2241766  
and SLC30A8 rs13266634), which have been related to dyslipidemia in HIV/HCV-coinfected 




Characteristics of patients 
The study included 263 patients, whose epidemiological and demographic characteristics are 
shown in Table 1. There were no significant differences between rs7903146 genotypes 
(TT/TC versus CC). 
Note that patients infected with HCV-GT3 had lower serum values of TC (p=0.013), LDL-C 
(p=0.014), and non-HDL-C (p=0.026) than patients infected with HCV-GT1 (Supplemental 
Figure 1). Furthermore, liver steatosis was found in higher percentage in HCV-GT3 patients 
(70.6% (36/51)) than HCV-GT1 patients (52.7% (58/110); p=0.032) and HCV-GT4 patients 
(47.1% (16/34); p=0.029).  
Frequencies of TCF7L2 polymorphism 
Allele frequencies for the TCF7L2 rs7903146 polymorphism were 0.64 for C allele and 0.36 
for T allele. Genotype frequencies for rs7903146 polymorphism were 0.42 for CC genotype, 
0.43 for TC genotype and 0.15 for TT genotype. These frequencies in our dataset were in 
accordance with data listed on the NCBI SNP database (http:// 
http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=7903146). The rs7903146 SNP 
fulfilled the minimum allele frequency (MAF)>0.05 and displayed less than 5% of missing 
values. Furthermore, rs7903146 was in Hardy-Weinberg equilibrium (p=0.396). 
Association of rs7903146 with lipids profile  
Patients with rs7903146 TT/TC genotype showed significantly lower TC serum levels (p=0.003; 
Figure 1A), LDL-C (p=0.004; Figure 1B), HDL-C (p=0.012; Figure 1C), and non HDL-C 
(p=0.013; Figure 1D) than CC carriers. When we stratified the patients by HCV genotype, 
rs7903146 TT/TC carriers infected with HCV-GT3 had diminished values of TC (p=0.019; 
Figure 1A), LDL-C (p=0.013; Figure 1B), and non HDL-C (p=0.020; Figure 1D). 
Patients with rs7903146 TT/TC genotype had diminished percentage of TC≥200 mg/dL 
(p=0.038; Figure 2A) and non HDL-C≥130 mg/dL (p=0.041; Figure 2D) and elevated 
percentage of HDL-C≤40 mg/dL (p=0.028; Figure 2C). When patients were stratified by HCV 
genotype, rs7903146 TT/TC carriers infected with HCV-GT3 had lower percentage of 
TC≥200 mg/dL (p=0.001. Figure 2A), whereas rs7903146 TT/TC carriers infected with HCV-
GT1 had a higher percentage of HDL-C≤40 mg/dL (p=0.018; Figure 2C). 
When adjusted regression was performed (Table 2), rs7903146 TT/TC carriers infected with 
HCV-GT3 were associated with lower values of TC (adjusted AMR (aAMR)=0.81; p=0.003), 
LDL-C (aAMR=0.67; p=0.001), non HDL-C (aAMR=0.75; p=0.002); and percentage of 
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TC≥200 mg/dL (adjusted OR (aOR)=0.89; p=0.037). An association between rs7903146 
TT/TC genotype and diminished levels of HDL-C (aAMR=0.91; p=0.049) and elevated 
percentage of HDL-C≤40 mg/dL (aOR)=3.26; p=0.003) were found in HCV-GT1 patents.  
10 
DISCUSSION 
In the present study, we evaluated for the first time the impact of the TCF7L2 rs7903146 
polymorphism on serum lipid profile in HIV/HCV-coinfected patients. The major findings were: 
(i) the rs7903146 TT/TC genotype (T allele) was related to lower fasting serum levels of TC, 
LDL-C and non HDL-C in HIV patients coinfected with HCV-GT3; (ii) rs7903146 TT/TC 
genotype was linked to diminished levels of HDL-C and elevated percentage of patients with 
HDL-C≤40 mg/dL among HIV patients coinfected with HCV-GT1. 
Several reports have analyzed the TCF7L2 polymorphism association with serum lipid 
disturbances in non-HIV/HCV-coinfected population, providing discordant results. Thus,  the 
presence of rs7903146 T allele disrupted the lipid metabolism, inducing low levels of HDL-C 
and apolipoprotein (Apo)-A1 in healthy young men (25), high levels of TG in familial 
combined hyperlipidaemia patients (37) and atherogenic lipoprotein profile in nonalcoholic 
fatty liver disease (38). Moreover, rs7903146 T allele has been linked to severity of coronary 
artery disease, higher death ratio by cardiovascular event and increased cardiovascular risk 
in non-diabetic individuals (39). In contrast, it has been described that rs7903146 T carriers 
show a favorable lipid profile with lower TG and higher HDL-C concentration (40). However, 
other studies did not find significant association between rs7903146 and lipid metabolism 
(41, 42). These inconsistencies could be due to different study designs (transversal, 
retrospective, cohorts, etc.), patient characteristics (age, race, etc.), environmental exposure 
(mainly diet), or underlying comorbidities (polycystic ovary syndrome, metabolic syndrome, 
type 2 diabetes mellitus, etc). 
The cardiovascular risk and atherosclerosis associated to CHC infection have been previously 
reported. For instance, HCV infection has related with carotid atherosclerosis, coronary artery 
stenosis and increased carotid intima-media thickness (43). According to the National 
Cholesterol Education Program Adult Treatment Plan Guideline III (NCEP ATP-III), the 
evaluation of total cholesterol, triglycerides, lipoproteins and several risk factors are useful to 
assess the person´s risk status for CHD (44). Elevated LDL-C is considered as a major risk 
factor. For this reason, this is the primary target of cholesterol-lowering therapy. Patients with 
CHD or equivalent risks should be treated for reaching a LDL <100 mg/dL (44). 
Nevertheless, the adequate interpretation of our data in the context of cardiovascular risk in 
coinfected patients is complicated, due to interactions between HIV, HCV and cART. For 
instance: (i) HIV infection is strongly related with lipid disturbances in cART-naïve patients, 
including reduced levels of TC, HDL-C and LDL-C, and elevated TG levels (45); (ii) cART 
induces increased levels of TC, LDL-C, and TG (13); (iii) HCV replication depends on lipid 
metabolism of host cells, which generates an increased lipid cellular content, membrane 
structures alterations and induces dyslipidemia, mainly represented by low circulating levels of 
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TC, LDL-C (2, 46) and HDL-C (46). For these reasons, we consider that the multivariate 
regression with continuous values of TC and lipoproteins could be a better indicator than 
thresholds to evaluate the impact of TCF7L2 polymorphism on relative cardiovascular risk in 
HIV/HCV-coinfected patients. 
It is previously described that patients with CHC have a lipid profile similar to familiar 
hypobetalipoprotinemia. These diminished levels on beta-lipoproteins are more commonly 
present in HCV-GT3 infection than HCV-GT1 (47). These facts are in agreement to our results, 
which reveal a key role of the rs7903146 polymorphism on beta-lipoprotein metabolism in 
patients infected with HCV-GT3. We observed that the presence of minor T allele at 
rs7903146 polymorphism was associated with a favorable cardiovascular profile represented 
by diminished serum levels of TC, non HDL-C and LDL-C among HCV-GT3 patients. In 
contrast, the rs7903146 T allele was correlated with lower levels of HDL-C and an elevated 
percentage of patients with T allele showed HDL-C≤40 mg/dL among the HCV-GT1 patients, 
which is considered as an independent risk factor by NCEP ATP-III  (44).  
Considering that the presence of the rs7903146 T allele was related with dislipidemia, the 
genotyping of TCF7L2 rs7903146 polymorphism could help to identify the individuals with 
lipid disturbances, opening the possibility to implement early treatment for these patients. 
However, the analysis of rs7903146 T allele for prediction of dyslipidemia according the 
NCEP ATP-III thresholds revealed a low diagnostic performance [area under the receiver 
operating characteristic curves (AUC-ROCs) <0.6 (data not shown)]. Thus, the utility of the 
rs7903146 polymorphism for prediction of dyslipidemia is limited according to our data, even 
though further extensive clinical research studies will be needed to clarify the impact of this 
SNP on cardiovascular disease of HIV/HCV coinfected patients. 
Many studies have described the interaction of HIV, HCV infection, and antiretroviral therapy 
to increase the risk of insulin resistance and T2DM (48, 49), although the mechanisms are 
not completely understood. Moreover, there is growing evidence that genetic background 
may contribute to differences between individuals in complex diseases (19, 50). A strong 
association between T2DM risk and TCF7L2 SNPs was reported by Grant et.al. (51). Next, 
genetic variations in TCF7L2 (particularly rs7903146) were related to T2DM (52) and glucose 
metabolism (53, 54). Later, the association between minor T allele of rs7903146 and T2DM 
was replicated in multiple different populations, as it is shown in independent meta-analyses 
by Cauchi et al. (55), Luo et al. (56), Tong et al. (57) and Peng et al. (24). Furthermore, T 
allele has been associated with increased proinsulin/insulin ratio, impaired beta cell function 
and hyperglycemia (54, 58-60). The participants of the present study were non diabetic 
HIV/HCV patients, but 34.6% showed insulin resistance (HOMA≥3.0). Nevertheless, an 
exhaustive analysis showed that the rs7903146 polymorphism was not related to HOMA values 
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in our HIV/HCV coinfected population (data nor shown). This lack of association with glucose 
metabolism could be due to the limited number of patients used in the stratified analysis, or 
also to the possible distortive effect of direct and indirect factors related to both HIV and HCV 
infections, and cART (48). Moreover, we must not discount the fact that our patients had a 
relatively low BMI (median: 22.5 kg/m2). 
The present study has several limitations that must be taken into account for the correct 
interpretation of the data: (i) this is a cross-sectional study with a limited number of patients, 
which could limit achieving statistically significant; (ii) lipid disturbances may be caused by 
several interacting genetic and environmental determinants, being complicated to find the 
true individual effects of each disease-associated factor; (iii) our study must also be 
performed in monoinfected and untreated patients in order to evaluate the effect of chronic 
hepatitis C, HIV infection and cART separately; (iv) our study was carried out entirely in 
Caucasians, therefore as the allele frequency differs among ethnicities (24), it would be 
necessary to perform an independent replication of this study in different ethnicities. 
CONCLUSIONS 
The TCF7L2 rs7903146 TT/TC genotype was associated with lower levels of TC, LDL, and 
HDL in HCV-GT3 patients, and lower levels of HDL-C in HCV-GT1 patients; suggesting a 
role in the cardiovascular disease and a potential use as biomarker in HIV/HCV-coinfected 
patients. Nevertheless, we consider that further analyses on a large population are needed to 




Acknowledgements: The authors thank the Spanish National Genotyping Center (CeGen) 
for providing the SNP genotyping services (http://www.cegen.org). 
14 
REFERENCES 
1. Collaboration ATC. Causes of death in HIV-1-infected patients treated with 
antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of America. 
2010;50(10):1387-96. Epub 2010/04/13. 
2. Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. Hepatitis C virus 
infection and its clearance alter circulating lipids: implications for long-term follow-up. 
Hepatology. 2009;50(4):1030-7. Epub 2009/09/30. 
3. Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV 
infection and the risk of acute myocardial infarction. JAMA internal medicine. 
2013;173(8):614-22. Epub 2013/03/06. 
4. Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C 
virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV 
medicine. 2010;11(7):462-8. Epub 2010/02/19. 
5. Samaras K. Metabolic consequences and therapeutic options in highly active 
antiretroviral therapy in human immunodeficiency virus-1 infection. J Antimicrob Chemother. 
2008;61(2):238-45. Epub 2007/12/12. 
6. Feeney ER MP. HIV and HAART-Associated Dyslipidemia. Open Cardiovasc Med J. 
2011;5:49-63.(doi):10.2174/1874192401105010049. Epub 2011 Feb 24. 
7. Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E. Associations of 
chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther. 
2013;37(6):647-52. Epub 2013/02/07. 
8. Negro F, Sanyal AJ. Hepatitis C virus, steatosis and lipid abnormalities: clinical and 
pathogenic data. Liver Int. 2009;29 Suppl 2:26-37. Epub 2009/02/24. 
9. Macias J, Berenguer J, Japon MA, Giron JA, Rivero A, Lopez-Cortes LF, et al. Fast 
fibrosis progression between repeated liver biopsies in patients coinfected with human 
immunodeficiency virus/hepatitis C virus. Hepatology. 2009;50(4):1056-63. Epub 2009/08/12. 
10. Lopez-Dieguez M, Montes ML, Pascual-Pareja JF, Quereda C, Von Wichmann MA, 
Berenguer J, et al. The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected 
patients. AIDS. 2011;25(7):899-904. Epub 2011/02/19. 
11. Crane HM, Grunfeld C, Willig JH, Mugavero MJ, Van Rompaey S, Moore R, et al. 
Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral 
therapy in clinical care. AIDS. 2011;25(2):185-95. Epub 2010/12/15. 
12. Buchacz K, Weidle PJ, Moore D, Were W, Mermin J, Downing R, et al. Changes in 
lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in 
the home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr. 
2008;47(3):304-11. Epub 2008/04/10. 
13. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection 
and HAART on serum lipids in men. JAMA : the journal of the American Medical Association. 
2003;289(22):2978-82. Epub 2003/06/12. 
15 
14. Montes ML, Pulido F, Barros C, Condes E, Rubio R, Cepeda C, et al. Lipid disorders 
in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, 
characterization and risk factors. J Antimicrob Chemother. 2005;55(5):800-4. Epub 
2005/03/12. 
15. Estrada V, Portilla J. Dyslipidemia related to antiretroviral therapy. AIDS reviews. 
2011;13(1):49-56. Epub 2011/03/18. 
16. Evaluating and managing cardiovascular disease risk factors in HIV-infected patients. 
Topics in HIV medicine : a publication of the International AIDS Society, USA. 
2010;18(5):164-8. Epub 2011/01/20. 
17. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. 
Combination antiretroviral therapy and the risk of myocardial infarction. The New England 
journal of medicine. 2003;349(21):1993-2003. Epub 2003/11/25. 
18. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of 
antiretroviral drugs and the risk of myocardial infarction. The New England journal of 
medicine. 2007;356(17):1723-35. Epub 2007/04/27. 
19. Wu Y, Waite LL, Jackson AU, Sheu WH, Buyske S, Absher D, et al. Trans-ethnic fine-
mapping of lipid loci identifies population-specific signals and allelic heterogeneity that 
increases the trait variance explained. PLoS genetics. 2013;9(3):e1003379. Epub 
2013/04/05. 
20. Pineda-Tenor D, Berenguer J, Garcia-Broncano P, Jimenez-Sousa MA, Fernandez-
Rodriguez A, Diez C, et al. Association of adiponectin (ADIPOQ) rs2241766 polymorphism 
and dyslipidemia in HIV/HCV-coinfected patients. European journal of clinical investigation. 
2014;44(5):453-62. Epub 2014/02/18. 
21. Pineda-Tenor D, Micheloud D, Berenguer J, Jimenez-Sousa MA, Fernandez-
Rodriguez A, Garcia-Broncano P, et al. SLC30A8 rs13266634 polymorphism is related to a 
favorable cardiometabolic lipid profile in HIV/hepatitis C virus-coinfected patients. AIDS. 
2014. Epub 2014/02/07. 
22. Jin T. The WNT signalling pathway and diabetes mellitus. Diabetologia. 
2008;51(10):1771-80. Epub 2008/08/13. 
23. Povel CM, Boer JM, Reiling E, Feskens EJ. Genetic variants and the metabolic 
syndrome: a systematic review. Obes Rev. 2011;12(11):952-67. Epub 2011/07/14. 
24. Peng S, Zhu Y, Lu B, Xu F, Li X, Lai M. TCF7L2 gene polymorphisms and type 2 
diabetes risk: a comprehensive and updated meta-analysis involving 121,174 subjects. 
Mutagenesis. 2013;28(1):25-37. Epub 2012/11/29. 
25. Perez-Martinez P, Perez-Caballero AI, Garcia-Rios A, Yubero-Serrano EM, Camargo 
A, Gomez-Luna MJ, et al. Effects of rs7903146 variation in the Tcf7l2 gene in the lipid 
metabolism of three different populations. PloS one. 2012;7(8):e43390. Epub 2012/08/24. 
26. Boccardi V, Ambrosino I, Papa M, Fiore D, Rizzo MR, Paolisso G, et al. Potential role 
of TCF7L2 gene variants on cardiac sympathetic/parasympathetic activity. European journal 
of human genetics : EJHG. 2010;18(12):1333-8. Epub 2010/07/22. 
27. Bonnet F, Roussel R, Natali A, Cauchi S, Petrie J, Laville M, et al. Parental history of 
type 2 diabetes, TCF7L2 variant and lower insulin secretion are associated with incident 
hypertension. Data from the DESIR and RISC cohorts. Diabetologia. 2013. Epub 2013/08/15. 
16 
28. Panel de expertos de Gesida Plan Nacional sobre el Sida y Asociación Española 
para el Estudio del Hígado. [Recommendations of Gesida/PNS/AEEH for the management 
and treatment of the adult patient co-infected with HIV and hepatitis A, B and C virus]. 
Enfermedades infecciosas y microbiologia clinica. 2010;28(1):31 e1-. Epub 2010/02/02. 
Recomendaciones de Gesida/PNS/AEEH sobre tratamiento y manejo del paciente adulto 
coinfectado por VIH y virus de las hepatitis A, B y C. 
29. Panel de expertos de Gesida y Plan Nacional sobre el Sida. [Recommendations from 
the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human 
immunodeficiency virus infection (update February 2009)]. Enfermedades infecciosas y 
microbiologia clinica. 2009;27(4):222-35. Epub 2009/02/28. Recomendaciones de 
Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos 
infectados por el virus de la inmunodeficiencia humana (actualizacion febrero de 2009). 
30. Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, et al. Risk of 
hepatitis C virus infection among young adult injection drug users who share injection 
equipment. Am J Epidemiol. 2002;155(7):645-53. Epub 2002/03/27. 
31. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-
density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin 
Chem. 1972;18(6):499-502. Epub 1972/06/01. 
32. Martinez-Hervas S, Real JT, Priego MA, Carratala A, Sniderman AD, Carmena R, et 
al. Establishing cut-off values for apolipoprotein B and non-HDL-C according to LDL-C 
values in a South European population. International journal of clinical practice. 
2013;67(1):81-8. Epub 2012/12/18. 
33. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 
Homeostasis model assessment: insulin resistance and beta-cell function from fasting 
plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9. Epub 
1985/07/01. 
34. Jacobs WH, Goldberg SB. Statement on outpatient percutaneous liver biopsy. 
Digestive diseases and sciences. 1989;34(3):322-3. Epub 1989/03/01. 
35. Resino S, Seoane JA, Bellon JM, Dorado J, Martin-Sanchez F, Alvarez E, et al. An 
artificial neural network improves the non-invasive diagnosis of significant fibrosis in 
HIV/HCV coinfected patients. The Journal of infection. 2011;62(1):77-86. Epub 2010/11/16. 
36. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. 
The METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289-93. Epub 1996/08/01. 
37. Huertas-Vazquez A, Plaisier C, Weissglas-Volkov D, Sinsheimer J, Canizales-
Quinteros S, Cruz-Bautista I, et al. TCF7L2 is associated with high serum triacylglycerol and 
differentially expressed in adipose tissue in families with familial combined hyperlipidaemia. 
Diabetologia. 2008;51(1):62-9. Epub 2007/11/01. 
38. Musso G, Gambino R, Pacini G, Pagano G, Durazzo M, Cassader M. Transcription 
factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and 
hepatocyte apoptosis in NASH. Hepatology. 2009;49(2):426-35. Epub 2008/12/24. 
39. Sousa AG, Marquezine GF, Lemos PA, Martinez E, Lopes N, Hueb WA, et al. 
TCF7L2 polymorphism rs7903146 is associated with coronary artery disease severity and 
mortality. PloS one. 2009;4(11):e7697. Epub 2009/11/20. 
17 
40. Melzer D, Murray A, Hurst AJ, Weedon MN, Bandinelli S, Corsi AM, et al. Effects of 
the diabetes linked TCF7L2 polymorphism in a representative older population. BMC 
medicine. 2006;4:34. Epub 2006/12/22. 
41. Cauchi S, Meyre D, Choquet H, Dina C, Born C, Marre M, et al. TCF7L2 variation 
predicts hyperglycemia incidence in a French general population: the data from an 
epidemiological study on the Insulin Resistance Syndrome (DESIR) study. Diabetes. 
2006;55(11):3189-92. Epub 2006/10/27. 
42. Kimber CH, Doney AS, Pearson ER, McCarthy MI, Hattersley AT, Leese GP, et al. 
TCF7L2 in the Go-DARTS study: evidence for a gene dose effect on both diabetes 
susceptibility and control of glucose levels. Diabetologia. 2007;50(6):1186-91. Epub 
2007/04/13. 
43. Loria P, Marchesini G, Nascimbeni F, Ballestri S, Maurantonio M, Carubbi F, et al. 
Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic 
and non-cirrhotic liver disease due to varying etiology. Atherosclerosis. 2014;232(1):99-109. 
Epub 2014/01/10. 
44. Executive Summary of The Third Report of The National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood 
Cholesterol In Adults (Adult Treatment Panel III). JAMA : the journal of the American Medical 
Association. 2001;285(19):2486-97. Epub 2001/05/23. 
45. Grunfeld C. Dyslipidemia and its Treatment in HIV Infection. Topics in HIV medicine : 
a publication of the International AIDS Society, USA. 2010;18(3):112-8. Epub 2010/10/06. 
46. Dai CY, Yeh ML, Huang CF, Hou CH, Hsieh MY, Huang JF, et al. Chronic hepatitis C 
infection is associated with insulin resistance and lipid profiles. Journal of gastroenterology 
and hepatology. 2013. Epub 2013/07/03. 
47. Vespasiani-Gentilucci U, Gallo P, De Vincentis A, Galati G, Picardi A. Hepatitis C 
virus and metabolic disorder interactions towards liver damage and atherosclerosis. World 
journal of gastroenterology : WJG. 2014;20(11):2825-38. Epub 2014/03/25. 
48. Kotler DP. Hepatitis C, human immunodeficiency virus and metabolic syndrome: 
interactions. Liver international : official journal of the International Association for the Study 
of the Liver. 2009;29 Suppl 2:38-46. Epub 2009/02/24. 
49. Eslam M, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Use 
of HOMA-IR in hepatitis C. Journal of viral hepatitis. 2011;18(10):675-84. Epub 2011/09/15. 
50. Norris JM, Rich SS. Genetics of glucose homeostasis: implications for insulin 
resistance and metabolic syndrome. Arteriosclerosis, thrombosis, and vascular biology. 
2012;32(9):2091-6. Epub 2012/08/17. 
51. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, et 
al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. 
Nature genetics. 2006;38(3):320-3. Epub 2006/01/18. 
52. Ruchat SM, Elks CE, Loos RJ, Vohl MC, Weisnagel SJ, Rankinen T, et al. 
Association between insulin secretion, insulin sensitivity and type 2 diabetes susceptibility 
variants identified in genome-wide association studies. Acta diabetologica. 2009;46(3):217-
26. Epub 2008/12/17. 
18 
53. Bonetti S, Trombetta M, Malerba G, Boselli L, Trabetti E, Muggeo M, et al. Variants 
and haplotypes of TCF7L2 are associated with beta-cell function in patients with newly 
diagnosed type 2 diabetes: the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 1. 
The Journal of clinical endocrinology and metabolism. 2011;96(2):E389-93. Epub 
2010/12/17. 
54. Stolerman ES, Manning AK, McAteer JB, Fox CS, Dupuis J, Meigs JB, et al. TCF7L2 
variants are associated with increased proinsulin/insulin ratios but not obesity traits in the 
Framingham Heart Study. Diabetologia. 2009;52(4):614-20. Epub 2009/02/03. 
55. Cauchi S, El Achhab Y, Choquet H, Dina C, Krempler F, Weitgasser R, et al. TCF7L2 
is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-
analysis. J Mol Med (Berl). 2007;85(7):777-82. Epub 2007/05/04. 
56. Luo Y, Wang H, Han X, Ren Q, Wang F, Zhang X, et al. Meta-analysis of the 
association between SNPs in TCF7L2 and type 2 diabetes in East Asian population. 
Diabetes Res Clin Pract. 2009;85(2):139-46. Epub 2009/06/02. 
57. Tong Y, Lin Y, Zhang Y, Yang J, Liu H, Zhang B. Association between TCF7L2 gene 
polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome 
Epidemiology (HuGE) review and meta-analysis. BMC Med Genet. 2009;10:15. Epub 
2009/02/21. 
58. Marzi C, Huth C, Kolz M, Grallert H, Meisinger C, Wichmann HE, et al. Variants of the 
transcription factor 7-like 2 gene (TCF7L2) are strongly associated with type 2 diabetes but 
not with the metabolic syndrome in the MONICA/KORA surveys. Horm Metab Res. 
2007;39(1):46-52. Epub 2007/01/18. 
59. Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR, et al. 
TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. 
The New England journal of medicine. 2006;355(3):241-50. Epub 2006/07/21. 
60. Helgason A, Palsson S, Thorleifsson G, Grant SF, Emilsson V, Gunnarsdottir S, et al. 
Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. 




STATEMENT OF INTERESTS 
Authorship Statement: The authors listed on the title page have contributed significantly to 
the work. The authors have nothing to disclose. The authors do not have any commercial or 
other association that might pose a conflict of interest. 
 
Personal Interest: DPT, MAJS, and MGA have received research funding from “Instituto de 
Salud Carlos III” [grant numbers CM12/00043, CM10/00105, and CD12/00442, respectively]. 
JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el 
Sistema Nacional de Salud (I3SNS). 
 
Funding Interest: This work has been supported by grants given by Fondo de Investigación 
de Sanidad en España (FIS) [Spanish Health Founds for Research] [grant numbers 
PI08/0738, PI11/00245; PI08/0928, and PI11/01556], and “Fundación para la Investigación y 
la Prevención del Sida en España” (FIPSE) [grant number 361020/10]. This work has been 
(partially) funded by the RD12/0017/0024 and RD12/0017/0004 projects as part of the Plan 
Nacional R + D + I and cofinanced by ISCIII- Subdirección General de Evaluación y el Fondo 
Europeo de Desarrollo Regional (FEDER). 
 
20 
Table 1. Clinical and epidemiological characteristics of all HIV/HCV-coinfected patients stratified by 
TCF7L2 genotype. Categorical variables were expressed in absolute numbers (%). Continuous variables 
were expressed in median (percentile 25; percentile 75).  
  rs7903146 
Characteristics All Patients TT/TC CC (*) p-value 
     
N  263 (100%) 152 (57.6%) 111 (42.1%) - 
Male 197 (74.9%) 117 (77%) 80 (72.1%) 0.365 
Age, years  40.8 (37.9; 44.7) 41.2 (38.2; 44.7) 40.2 (37.5; 44.8) 0.280 
BMI, kg/m2  22.5 (20.9; 24.7) 22.3 (20.8; 24.5) 22.9 (21.5; 25.1) 0.142 
BMI ≥25 kg/m2 61 (23.3%) 33 (21.9%) 28 (25.9%) 0.527 
HOMA 2.1 (1.3; 3.7) 2 (1.3; 3.8) 2.3 (1.3; 3.5) 0.215 
    HOMA ≥3 91 (34.6%) 51 (33.6%) 40 (36%) 0.676 
Years since HCV infection 20.9 (14.6; 24.4) 20.7 (15.4; 25.1) 21.7 (17.5; 24.0) 0.904 
Prior AIDS 77 (29.3%) 48 (31.6%) 29 (26.1%) 0.337 
cART 222 (84.4%) 130 (85.5%) 92 (82.9%) 0.559 
Time on cART, years  4.7 (2.9; 7.8) 4.9 (3; 8) 4.7 (2.5; 7.4) 0.235 
Current cART protocols,      
Any NRTIs + any PI  64 (24.3%) 37 (24.3%) 27 (24.3%) 0.997 
Any NRTIs + PI + NNRTI  3 (1.1%) 2 (1.3%) 1 (0.9%) 0.754 
Any NRTIs + any NNRTI  134 (51%) 82 (53.9%) 52 (46.8%) 0.255 
Only NRTIs  20 (7.6%) 8 (5.3%) 12 (10.8%) 0.094 
Antiretroviral drugs     
Zidovudine 72 (27.4%) 42 (27.6%) 30 (27%) 0.914 
Stavudine 67 (25.5%) 38 (25.0%) 29 (26.1%) 0.836 
Didanosine 43 (16.3%) 21 (13.8%) 22 (19.8%) 0.193 
Tenofovir 72 (27.4%) 43 (28.3%) 29 (26.1%) 0.698 
Abacavir 43 (16.3%) 25 (16.4%) 18 (16.2%) 0.960 
Efavirenz  80 (30.4%) 48 (31.6%) 32 (28.8%) 0.632 
Ritonavir (r) 16 (6.1%) 12 (7.9%) 4 (3.6%) 0.150 
Lopinavir/r 32 (12.2%) 17 (11.2%) 15 (13.5%) 0.568 
Saquinavir  3 (1.1%) 1 (0.7%) 2 (1.8%) 0.388 
Fosamprenavir  6 (2.3%) 3 (2.0%) 3 (2.7%) 0.696 
HIV markers     
Nadir CD4+, cells/μL  208 (92.3; 314.8) 191.5 (93.8; 301.5) 228 (83; 349) 0.351 
Nadir CD4+ <200 cells/μL 128 (48.7%) 80 (52.6%) 48 (43.2%) 0.132 
CD4+ T, cells/μL  462 (338; 667) 464.5 (323.3; 657.8) 461 (363; 684) 0.688 
CD4+ ≥500 cells/μL  113 (43.1%) 67 (44.1%) 46 (41.8%) 0.715 
HIV-RNA <50 copies/mL 202 (77.1%) 112 (73.7%) 90 (81.8%) 0.122 
HCV markers, n (%)       
HCV-GT 1 142 (55.7%) 83 (56.8%) 59 (54.6%) 0.665 
HCV-GT 2 5 (2%) 4 (2.7%) 1 (0.9%) 0.299 
HCV-GT 3 65 (25.5%) 38 (26%) 27 (24.8%) 0.820 
HCV-GT 4 43 (16.8%) 21 (14.4%) 22 (20.2%) 0.221 
HCV-RNA ≥500.000 IU/ml 189 (75.3%) 110 (75.9%) 79 (74.5%) 0.809 
Metavir score     
Liver biopsy patients 211 (80.3%) 119 (93%) 92 (92%) 0.782 
Significant fibrosis (F≥2) 103 (48.8%) 52 (43.7%) 51 (55.4%) 0.092 
Moderate activity (A≥2) 108 (51.9%) 56 (47.5%) 52 (57.8%) 0.140 
 
Abbreviations: AIDS, acquired immunodeficiency syndrome; BMI, body mass index; cART, combination 
antiretroviral therapy; HCV, hepatitis C virus; HCV-RNA, HCV plasma viral load; GT, genotype; HIV, human 
immunodeficiency virus; HIV-RNA, HIV plasma viral load; HOMA, homeostatic model assessment; IVDU, 
intravenous drug users; NNRTI, no nucleoside analog reverse-transcriptase inhibitors; NRTI, nucleoside 
analog reverse-transcriptase inhibitors; PI, protease inhibitors.  
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Table 2. Summary of adjusted association between rs7903146 TT/TC genotype and lipid profile stratified by HCV genotype in HIV/HCV coinfected patients.  
 
 All Patients HCV-GT1 HCV-GT3 HCV-GT4 
Concentration(a) AMR (95% CI)  p-value AMR (95% CI)  p-value AMR (95% CI)  p-value AMR (95% CI)  p-value 
TC, mg/dL 0.91 (0.84; 0.97) 0.006 0.93 (0.85; 1.02) 0.133 0.81 (0.70; 0.93) 0.003 0.91 (0.75; 1.01) 0.325 
LDL-C, mg/dL 0.88 (0.79; 0.98) 0.016 0.93 (0.81; 1.06) 0.263 0.67 (0.54; 0.84) 0.001 0.85 (0.66; 1.11) 0.227 
HDL-C, mg/dL 0.91 (0.84; 0.98) 0.012 0.91 (0.82; 1.00) 0.049 0.89 (0.80; 1.00) 0.052 0.89 (0.76; 1.03) 0.107 
Non HDL-C, mg/dL 0.90 (0.82; 0.98) 0.016 0.94 (0.84; 1.05) 0.255 0.75 (0.63; 0.90) 0.002 0.91 (0.71; 1.17) 0.460 
TG, mg/dL 0.99 (0.91; 1.10) 0.925 1.00 (0.89; 1.13) 0.970 1.12 (0.96; 1.30) 0.147 0.89 (0.70; 1.11) 0.291 
         
ATP III Classification(b) OR (95% CI)  p-value OR (95% CI)  p-value OR (95% CI)  p-value OR (95% CI)  p-value 
TC≥200 mg/dL 0.49 (0.21; 1.09) 0.079 1.01 (0.34; 2.99) 0.983 0.89 (0.09-0.86) 0.037 0.47 (0.06; 3.38) 0.450 
LDL-C≥100 mg/dL 0.77 (0.44; 1.37) 0.374 0.86 (0.40; 1.88) 0.707 0.77 (0.21; 2.83) 0.690 1.72 (0.39; 7.65) 0.475 
HDL-C≤40 mg/dL 1.96 (1.15-3.36) 0.014 3.26 (1.49-7.16) 0.003 1.72 (0.53-5.55) 0.364 2.05 (0.41-10.12) 0.380 
Non HDL-C≥130 mg/dL 0.61 (0.35-1.07) 0.087 0.71 (0.34-1.47) 0.360 0.62 (0.17-2.21) 0.464 0.61 (0.15-2.45) 0.487 
TG≥150 mg/dL 0.59 (0.33-1.04) 0.067 0.72 (0.33-1.55) 0.399 0.27 (0.06-1.23) 0.091 0.16 (0.02-1.30) 0.087 
 
(a), Multivariate lineal regression was performed to compare the serum lipid values, which were log10-transformed; (b), Logistic regression was performed to 
compare categorical variables. Both tests were adjusted by significant epidemiological and clinical factors [age, gender, BMI, nadir CD4+, CD4+ T cells/µL, 
HIV plasma viral load, HCV plasma viral load, time on CART, specific antiretroviral drugs and related SNPs]. Statistically significant differences are shown in 
bold. 
Abbreviations: AMR, arithmetic mean ratio (how many times greater is the value in the presence of TT/TC genotype versus CC genotype); OR, odds ratio 
(likelihood of having the outcome in the CT/TT genotype versus CC genotype); CI, confidence interval; GT, genotype; HCV, hepatitis C virus; HDL-C, High-
density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides.  
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Figure 1. Summary of the unadjusted association between TCF7L2 rs7903146 and the concentration of 
serum lipid profile among HIV/HCV-coinfection. Variables were expressed in median (interquartile range). 
P-values were calculated by univariate linear regressions. Statistically significant differences were shown in 
bold. 
Abbreviations: GT, genotype; HCV, hepatitis C virus; HDL-C, High-density lipoprotein cholesterol; LDL-C, 
low-density lipoprotein cholesterol.  
 
Figure 2. Summary of the unadjusted association between TCF7L2 rs7903146 and the NCEP ATP-III 
characteristics among HIV/HCV-coinfection. Variables were expressed in percentages. P-values were 
calculated by univariate logistic regressions. Statistically significant differences were shown in bold. 
Abbreviations: GT, genotype; HCV, hepatitis C virus; HDL-C, High-density lipoprotein cholesterol; LDL-C, 
low-density lipoprotein cholesterol.  
 
Supplemental Figure 1. Serum lipid profile in HIV/HCV coinfected patients according to HCV genotype. 
Variables were expressed in median (interquartile range). P-values were calculated by Mann Whitney U 
test. Statistically significant differences were shown in bold. 
Abbreviations: GT, genotype; HCV, hepatitis C virus; HDL-C, High-density lipoprotein cholesterol; LDL-C, 
low-density lipoprotein cholesterol. 
 
 
 
 
 
 
